Behavioral Problems in Fragile X Syndrome: A Review of Clinical Management.

Autor:	Davidson M; Pediatrics, Larkin Community Hospital, South Miami, USA., Sebastian SA; Research, Larkin Community Hospital, South Miami, USA., Benitez Y; Pediatrics, Larkin Community Hospital, South Miami, USA., Desai S; Research, Larkin Community Hospital, South Miami, USA., Quinonez J; Neurology/Osteopathic Neuromuscular Medicine, Larkin Community Hospital, South Miami, USA., Ruxmohan S; Neurology, Larkin Community Hospital, South Miami, USA., Stein JD; Osteopathic Neuromuscular Medicine, Family Medicine, Sports Medicine, Pain Medicine, Lake Erie College of Osteopathic Medicine (LECOM) Bradenton, Bradenton, USA.; Pain Management, Osteopathic Neuromuscular Medicine, Sports Medicine, Larkin Community Hospital, South Miami, USA., Cueva W; Neurology, Larkin Community Hospital, South Miami, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2022 Feb 02; Vol. 14 (2), pp. e21840. Date of Electronic Publication: 2022 Feb 02 (Print Publication: 2022).
DOI:	10.7759/cureus.21840
Abstrakt:	Fragile X syndrome (FXS) is noted to be the leading cause of inherited intellectual disabilities and is caused by expansive cytosine-guanine-guanine (CGG) trinucleotide repeats in the fragile X mental retardation 1 gene (FMR1). FXS can display a wide range of behavioral problems in addition to intellectual and developmental issues. Management of these problems includes both pharmacological and non-pharmacological options and research on these different management styles has been extensive in recent years. This narrative review aimed to collate recent evidence on the various management options of behavioral problems in FXS, including the pharmacological and non-pharmacological treatments, and also to provide a review of the newer avenues in the FXS treatment. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Davidson et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu